Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Gauckler, P; Regele, H; Eller, K; Säemann, MD; Lhotta, K; Zitt, E; Neumann, I; Rudnicki, M; Odler, B; Kronbichler, A; Windpessl, M.
[Diagnosis and treatment of Minimal Change Disease in adults-2023].
Wien Klin Wochenschr. 2023; 135(Suppl 5): 628-637. Doi: 10.1007/s00508-023-02258-5 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz

Eller Kathrin

Odler Balazs

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

Minimal change disease is a glomerulopathy that clinically manifests as acute onset nephrotic syndrome. A diagnosis is made by renal biopsy, implying the absence of glomerular lesions on light microscopy but detection of extensive podocyte foot process effacement on electron miscroscopy. Considering the typically excellent response to immunosuppressive measures (especially to glucocorticoids), an autoimmune pathogenesis is assumed. Although general prognosis is overall beneficial, steroid-dependent, steroid-resistant and frequently-relapsing disease courses may complicate the management of these patients and necessitate the use of alternative immunosuppressive treatment strategies. Here, the Austrian Society of Nephrology (ÖGN) provides a consensus on how to best diagnose and manage adult patients with minimal change disease.

Find related publications in this database (using NLM MeSH Indexing)

Humans - administration & dosage

Adult - administration & dosage

Nephrosis, Lipoid - diagnosis, therapy

Austria - administration & dosage

Consensus - administration & dosage

Disease Progression - administration & dosage

Nephrology - administration & dosage

Nephrotic Syndrome - administration & dosage

Find related publications in this database (Keywords)

Minimal Change Disease

Podocytopathy

Glucocorticoids

© Med Uni Graz • Imprint